Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Case report

Pegfilgrastim

Asthenia: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Lee A, et al. An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer. Breast 72: Dec 2023. Available from: URL: http://doi.org/10.1016/j.breast.2023.103585 Lee A, et al. An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer. Breast 72: Dec 2023. Available from: URL: http://​doi.​org/​10.​1016/​j.​breast.​2023.​103585
Metadaten
Titel
Pegfilgrastim
Asthenia: case report
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-49288-9

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Antipsychotics

Case report

AZD-1222

Case report

Vancomycin

Case report

Antineoplastics

Case report

Multiple drugs